the particular clinical presentation of lichenoid drug eruption, the differential diagnosis may also include a number of other conditions such as lichen sclerosus, psoriasis, discoid lupus, graft-vs-host disease, and secondary syphilis.
The intention of our article was to provide a clear and concise introduction to lichenoid drug eruption, rather than dwell on the subtleties of the differential diagnosis. We agree that in cases in which the clinical diagnosis "was so clinically clear that no other diagnosis was considered," there is little point in subjecting a patient to a skin biopsy. We would go 1 step further to recommend that a biopsy not be performed unless the results could alter clinical management. However, when considering inflammatory dermatoses (including lichenoid drug eruption) with overlapping clinical patterns and divergent treatment approaches, the skin biopsy is of tremendous importance in reaching an accurate diagnosis, especially when performed by a dermatologist. 3, 4 With respect to our patient, we would have recommended discontinuation of lisinopril with every differential diagnosis. However, our definitive diagnosis allowed us to (1) more accurately counsel the patient regarding the expected time course and resolution of her eruption, (2) advise her of potential associated symptoms, (3) recommend alternative antihypertensives that are not likely to induce her particular eruption, and (4) have a treatment plan in place in the event that her eruption failed to resolve or worsened. In general, a biopsy early in the clinical course of an eruption-and prior to any physician-or patient-initiated treatment-provides the most definitive, accurate, and cost-effective result.
Finally, although our patient's history was relatively straightforward and lent itself well to the teaching purposes of the article, most cases are not so clear-cut. Lichenoid drug eruptions have an extremely variable latency period (from weeks to years) and can be induced by numerous medications. It is frequently much more difficult to determine whether the eruption is drug-induced than it was in this case. In addition, the discontinuation of a potential culprit medication may have much more serious implications for the patient. As discussed in the article, histological features are often helpful in differentiating idiopathic lichen planus from lichenoid drug eruption. 
RESEARCH LETTER

National Trends in Ambulance Use by Patients With Stroke, 1997-2008
To the Editor: Thrombolytic therapy improves outcomes after ischemic stroke, but most patients are ineligible because they do not present in time. 1 This has prompted efforts to educate people to call 911 for signs of stroke because ambulance transportation results in faster arrival at the emergency department (ED). 2 Regional studies have suggested suboptimal ambulance use among patients with stroke, 3 but none has examined a nationally representative population or temporal trends since the approval of thrombolysis.
Methods. We analyzed data collected by the National Hospital Ambulatory Medical Care Survey (NHAMCS) between 1997 and 2008. 4 A nationally representative random sample of 340 to 408 EDs was surveyed annually, reflecting a participation rate of 87% to 98% and constituting approximately 10% of US EDs. Staff used structured forms to collect data about a systematic random sample of patients over a random 4-week period. Analysis of this publicly available deidentified data set was exempt from evaluation by our institutional review boards.
We included patients with a primary diagnosis of ischemic stroke, defined by International Classification of Diseases, Ninth Revision codes that have been validated for identifying patients with acute stroke and used in other studies. 5 Additionally, we included patients with subarachnoid hemorrhage, intracerebral hemorrhage, and transient ischemic attack because these can present similarly to ischemic stroke. Our outcome was arrival at the ED via ambulance. We used survey visit weights provided by the NHAMCS to estimate the national proportion of patients diagnosed with stroke in the ED each year who arrived by ambulance. We examined trends within subgroups defined by characteristics associated with ambulance use: age, sex, race, payment source, geographic region, and stroke subtype. 6 We performed sensitivity analyses limited to ischemic stroke and excluding patients not admitted to the hospital or with additional ED diagnoses besides stroke.
A survey-weighted 2 test for trend was used to examine the statistical significance of changes in ambulance use over time. We used multiple logistic regression to analyze yearly trends in ambulance use for stroke while controlling for covariates. Comment. Using data from a nationally representative sample of ED visits, we found that the proportion of patients with stroke who present via ambulance has not significantly changed over the past decade. Our analysis lacked power to detect temporal changes in subgroups. We could not determine what proportion of stroke diagnoses represented miscoding or mimics of stroke; however, our results were robust across sensitivity analyses addressing possible misclassification of cases. Several factors may explain static ambulance use since the approval of time-sensitive therapy for ischemic stroke. Educational efforts may not be adequately addressing poor public knowledge about stroke, additional behavioral barriers may remain among those with adequate knowledge, or the response of health care providers to patients with stroke symptoms may be imperfect. 3 Our findings suggest that national efforts to address barriers to ambulance use among patients with stroke need to be intensified or adjusted.
